Biomedit

About Biomedit

Biomedit operates at the intersection of microbiome science and animal health, developing novel products to address unmet needs in the sector. The company was established in April 2022, originating as a strategic carve-out of the microbiome research and development platform from Elanco Animal Health, in a partnership with synthetic biology firm Ginkgo Bioworks. This foundation provided Biomedit with a mature R&D pipeline, intellectual property, and an experienced scientific team from its inception.

The company is led by CEO Aaron Schacht, a seasoned executive with a deep background in the pharmaceutical and animal health industries. Schacht's journey includes a 25-year career at Eli Lilly and Company, followed by a tenure as Executive Vice President at Elanco, where he spearheaded innovation, regulatory affairs, and business development. His direct experience in leading the very microbiome R&D team that now forms the core of BiomEdit underscores the company's strategic direction and technical foundation. This move was driven by the belief that as a focused, venture-backed entity, the platform could accelerate its growth and innovation potential more effectively than within a large corporation.

Biomedit's business model is centered on the discovery and commercialization of microbiome-based products, including engineered probiotics and bioactives, for both livestock and companion animals. Revenue generation is structured through a mix of direct-to-market sales and strategic partnerships. For instance, a long-term agreement with Nutreco, a global leader in animal nutrition, grants them commercial rights to specific feed additive technologies. For other products, like their lead candidate BE-101, Biomedit plans to approach concentrated markets such as the U.S. broiler industry directly, while utilizing distributors for international markets. The company also actively secures non-dilutive funding through grants from organizations like the Bill & Melinda Gates Foundation and the USDA to advance research in areas such as methane reduction and avian influenza.

The company's core offering is its proprietary platform that combines a massive microbiome database—built from over 10,000 animal samples—with high-throughput microbiology, synthetic biology, and predictive AI algorithms. This allows Biomedit to identify and engineer microbes to perform specific functions. A primary product, BE-101, is an engineered probiotic designed to protect broiler chickens from necrotic enteritis by producing antibodies that neutralize the toxins from C. perfringens. This product is in the final phase of the USDA conditional licensure process, with a projected commercial launch in 2026. Other pipeline products include solutions for reducing methane emissions in cattle and therapeutics for metabolic diseases in cats, showcasing the platform's wide applicability.